Smaller firms should heed scientific advice to improve chances of success, says EMEA
This article was originally published in SRA
Since the European Medicines Agency opened its office for micro-, small- and medium-sized enterprises three years ago, 38 such companies have submitted marketing authorisation applications for new products, of which 33 were for human-use drugs and five for veterinary medicines, according to the office’s latest report1.
You may also be interested in...
Coronavirus Notebook: Italy Makes First Use Of EU’s Vaccine Export Control System, More Regulators Issue Guidance On Variants
Ukraine has established a system for issuing emergency use authorizations for COVID-19 vaccines that recognizes authorizations granted by other world regulators.
The Russian backers of the vaccine’s development say that if it receives a marketing authorization in the EU, distribution could begin in June this year.
Coronavirus Notebook: EU Moots Emergency Use Authorization Scheme For Vaccines, Janssen Product Up For 11 March Approval
Celltrion’s regdanvimab is undergoing an emergency use procedure in Europe, the European Medicines Agency and the health authorities in Canada have jointly published clinical data on the Moderna vaccine, and Canada has approved two versions of the AstraZeneca/Oxford University jab.